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Objectives: Cost effectiveness analyses play a critical role in determining cov-
erage of novel drugs and devices. Increasingly, payers are demanding subgroup 
analyses to determine indications which would be covered by the national health 
system or insurance agency. MethOds: To understand and review trends in the 
use of subgroup cost effectiveness analysis, we analyzed NICE HTAs for products 
approved between 2011-2012. Manufacturer submissions for CEA were compared 
to final review and decision by HTA agency. Analogs were identified and case 
studies were developed to further understand the use of subgroup analyses and 
cost effectiveness models. Results: Decisions made by NICE in 2011-2012 show 
increasing trends towards the use of subgroup analysis for determining indi-
cations for coverage by national payer bodies. Between 2011-2012, 80% of the 
assessments included subgroup analyses. Approximately half of them included 
cost effectiveness analyses for various subgroups. Interestingly, the ICER values 
estimated by NICE for the same subgroups showed a large variation (1X-3X fold 
difference) compared to ICER values estimated by manufacturers. Selected case 
studies highlighted that for several products, NICE is recommending treatments 
only for subgroups whose ICER values are within the cost effectiveness thresh-
old. cOnclusiOns: New products need robust broader population and subgroup 
analyses for insurance coverage.
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THe HTa RegulaTion on THe BRazilian HealTH CaRe SySTem and 
iTS imPaCT on FedeRal SPending on HealTH TeCHonologieS SuPPly 
THRougH lawSuiTS
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Objectives: To analyze the impact of changes in Brazil’s health care system leg-
islation from 2009 (CITEC) and after 2011 (CONITEC) on lawsuits for health tech-
nologies supply and federal spending. MethOds: Survey of federal spending in 
health technologies supply through lawsuits. Results: Lawsuits with the federal 
government as a defendant for health technologies supply started in 2002. Ten years 
later there were 3,205 individual lawsuits for which the government spent US$ 
131.19 million. The number of lawsuits continued to grow, reaching 2,273 in 2008. 
Since 2009, the growth rate slowed, reaching the annual average of 1,579, showing 
a stabilizing trend over the last 3 years. Federal spending grew at an average rate of 
150% per year: 221% per year until 2008, decelerating to 60% per year since 2008. The 
impact of these lawsuits creates a cumulative effect in federal spending because 
the technologies provided are for chronic diseases and continuous use. In 2012 and 
2013, 5 medicines alone, all of them indicated for the treatment of rare diseases 
(e.g. idursulfase, galsulfase and eculizumab) represent more than 80% of the fed-
eral spending. cOnclusiOns: Escalating lawsuits over the last decade in Brazil 
led to several initiatives that culminated with the publication of law 12,401/2011 
that created the National Committee for Health Technology Incorporation to assist 
the Ministry of Health in the incorporation of new technologies in Brazil’s health 
care system. The law established a deadline of 180 days for a decision to be made, 
based on scientific evidence of efficiency, accuracy, effectiveness and security, and 
on a comparative cost-benefit evaluation in relation to the technologies already 
incorporated. Decision must consider social participation, be clear and compre-
hensible. The deceleration in the annual rates of new lawsuits and the decrease in 
federal spending demonstrate that HTA applied to regulation may play a critical 
role in this context.
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Objectives: In the last years HTA-Scientific-Advice (HTA-SA) has been assuming 
a relevant role in decision process for assessment of new technologies for pricing 
and reimbursement in Europe. Since the beginning of the SA-initiatives, AIFA has 
been involved in multi-dimensional and multi-national advices: parallel-SA with 
European Medicines Agency (EMA), European-Network of HTA (EUnetHTA) Early-
Dialogue, Tapestry Networks, National HTA-SA. The AIFA-HTA-SA procedure relates 
the assessment of manufacturer’s briefing book; consultancies with clinical and HTA 
experts; face-to-face meeting with manufacturer and final report. This study aims 
at presenting an analysis of the HTA-SA programs over the last 3 years. MethOds: 
Comparative analysis of issues evaluated in different types of HTA-SA has been 
conducted, in terms of clinical development program (patients’characteristics and 
selection; choice of comparator; trial design; choice of endpoints, including patient-
reported-outcomes, stratification/subgroups; safety), cost-effectiveness (modeling, 
resource utilization, utility values) and Place in Therapy (value proposition, added 
benefit). Finally, an analysis of concordance between manufacturers proposal and 
AIFA-advice has been performed. Results: From 2011 to 2013, a total of 21 HTA-SAs 
were performed: 3 Tapestry-Networks-SAs; 3 National-HTA-SAs; 7 EUnetHTA-Early-
Dialogues; 8 parallel-EMA-HTA-SAs. Nervous system and cancer diseases were the 
main therapeutic areas of requests, accounting for 57% of total HTA-SAs (respec-
tively 6 products for each). The majority (52,4%) of HTA-SAs were requested in an 
early stage of clinical development (Phase I-II). The comparative analysis showed 
that clinical development items were systematically analysed among different types 
of HTA-SA, while the domains of cost-effectiveness and place in therapy were more 
relevant for EUnetHTA Early Dialogues and National HTA-SAs. The concordance 
analysis showed that target population, stratification/subgroups and choice of 
comparator(s) were critical issues. cOnclusiOns: The HTA-SA-activities respond 
to the emerging need of early interaction among manufacturers, regulators and 
HTAs. Different types of HTA-SA reflect different institutional bodies approaches 
and peculiarities. The National-HTA-SA-program is expected to increase in the next 
future.
study was conducted among general public in Quetta, Pakistan by using a conveni-
ent sampling technique. A total of one thousand respondents were approached and 
927 consumers participated in the survey giving a response rate of 92.7%. Data was 
analyzed by using SPSS version 18.0 and descriptive statistics were reported where 
appropriate. Results: Majority of the respondents (n= 609, 65.7%) were not aware 
of possible side effects of their current medications. A total of 144 respondents 
(15.5%) believed that all medicines registered in Pakistan are safe to use and they 
do not have any side effects. About 44.4% (n= 412) of the respondents claimed that 
they share their unused medicines with family and friends who are having similar 
illness. Majority of respondents 87.7% (n= 813) were not satisfied with the drug 
information provided by the health care professionals. The present study also found 
that more than 80% of the respondents (n= 742) did report that they never read the 
labels of their medication before using. cOnclusiOns: The present study revealed 
poor level of public knowledge regarding medication safety. It is evident that public 
underestimates the risk of their medications. There is a general lack of awareness 
and understanding among the public especially towards side effects.
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ConTRiBuTion oF HealTH eConomiCS & ouTComeS ReSeaRCH STudieS oF 
ColomBia To iSPoR ConFeRenCeS
Gutierrez-Ardila M.V, Vargas Zea N.
Pfizer S.A.S., Bogotá, Colombia
Objectives: The aim of this analysis was to summarize the contribution of Colombian 
papers to ISPOR conferences from 1998 to 2013. MethOds: It was developed a review 
of ISPOR Scientific Presentations Database from 1998 to 2013, filtering by abstract, 
by the word “Colombia” for each ISPOR meeting (International, European, Asian, and 
Latin American), we obtained a list of all abstracts those ones without Colombian 
authors were excluded. Abstracts were classified by disease, topic, and topic sub-
category taking into account the register of each one. It was taken into account if 
authors or abstract relate any support of pharmaceutical or/and devices industry. 
Descriptive statistics were applied by disease and study type. Results: A total of 258 
abstracts were identified, 25 were excluded because they have no Colombian authors; 
233 abstracts were included in the analysis, 111 from International (47.6%), 12 from 
European (5.2%), 1 from Asia-Pacific (0.4%) and 109 from Latin America Conference 
(46.8%). Over time, cumulative numbers of abstracts are increasing exponentially. The 
majority of abstracts were costs studies (76.4%), followed by Health Care Use & Policy 
Studies (13.3%), Clinical Outcomes Studies (6.0%), and others (10, 4.3%). The three 
most frequent diseases were cancer (12.4%), vaccine (12.0%) and infections (10.3%). 
The three most frequent cost studies developed were classified as cost-effectiveness 
analysis (61.8%), Cost of Illness studies (10.7%) and budget impact analysis (9.0%); 
Of included studies, 51.9% contain any author related with pharmaceutical or/and 
devices industry. There may be underreporting of studies due the filter was applied 
only for abstract content, neither by title nor authors; underreport on Scientific 
Presentations Database; and underreporting of pharmaceutical industries support 
due it is not disclosed on abstract. cOnclusiOns: The contribution of Colombia to 
ISPOR Conferences have been increasing markedly, going from 1 paper presented in 
2004 to 93 papers presented in 2013
HealTH CaRe uSe & PoliCy STudieS – Health Technology assessment Pro-
grams
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HealTH TeCHnology aSSeSSmenT (HTa) aCTiviTy woRldwide duRing 
2012 and 2013: main TRendS
Skaltsa K.1, Heemstra L.2, Tao C.3, Van Engen A.2
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Objectives: HTA activity is constantly growing over time at a global level, a trend 
observed in both countries with well-consolidated HTA agencies, such as the UK, 
as well as in HTA-emerging countries, such as Brazil. The objective of this study 
was to explore trends in HTA activity during 2012 and 2013 worldwide, along with 
flagging newcomers. MethOds: Data were obtained from the Quintiles HTA Watch 
platform covering almost 100 HTA agencies in 32 countries. Published and ongo-
ing HTA are captured in the database on a regular basis. Entries published from 1st 
of January 2012 till 31stof December 2013 were selected. The number of published 
reports by each agency and country/region was counted and were also stratified 
by therapeutic area and indication. Data from selected agencies based on their 
impact on reimbursement decisions were further explored. Results: 3241 reports 
were found in total for all agencies monitored, out of which 1530 were published 
in 2012 and 1659 in 2013. HTA Activity in the UK is constantly rising as a total (214 
reports published in 2012 and 254 in 2013 from NICE, SMC and AWMSG), as well as 
in the individual agencies (NICE experimented a 28% increase in the number of 
published reports). Increasing trends were also observed in France, Sweden, Canada 
and Australia, while Germany and Spain remained rather stable. Cancer, diabetes, 
digestive and musculoskeletal indications were the object of more evaluations in 
2013 compared to 2012, while cardiovascular and central nervous systems indica-
tions experimented a decline in selected agencies. Newcomers include Colombia 
with IETS and more than 50 reports, and Spain with the Therapeutic Positioning 
Reports. cOnclusiOns: Global statistics allowed us to describe trends in HTA activ-
ity that reinforce the conviction that evidence-based decisions are increasingly 
considered valuable/mandatory for reimbursement purposes and consequently, 
HTA activity is constantly in rise over the globe.
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need FoR SuBgRouP CoST eFFeCTiveneSS analySeS FoR HealTH 
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issued by CDR, 143 were negative and INESSS agreed with CDR in 90% of these 
recommendations. 132 of CDR’s recommendations were negative, of which INESSS 
agreed in 48% of cases. cOnclusiOns: INESSS has a higher positive recommen-
dation rate and, possibly due to the broader scope for funding recommendations, 
frequently disagrees with CDR’s analysis, particularly when CDR’s recommenda-
tion is negative.
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inTeRnaTional HTa ReFeRenCing – a RealiTy?
Sealey S.1, Edathodu A.1, Mukku S.R.2
1Access Partnership, London, UK, 2The Access Partnership, London, UK
Objectives: Countries already have a long history of referencing each other on 
drug prices through International price Referencing. However it is still unclear 
whether a similar kind of referencing exists for overall market access decisions. 
The objective of this report is 3 fold: first to identify if decision referencing exists 
between these countries and if yes how. Secondly to understand the extent of 
influence one country might have over another, and thirdly whether this process 
is formal or informal. MethOds: The research was conducted through in-depth 
secondary research and interviews with stakeholders in 14 countries including the 
UK, Ireland, Germany, France, Spain, Portugal, Italy, Sweden, Canada, Australia, The 
Netherlands, Austria, Hungary and Poland Results: NICE (UK), SMC (Scotland), 
and AWMSG (Wales) represent the more sophisticated attempts to integrate HTA 
into the decision-making process and are currently the most influential HTAs in 
the world with over 60 countries referencing them worldwide. IQWiG (Germany), 
HAS (France), TLV (Sweden), and HSE (Ireland) form the medium influence HTA 
agencies. This can be attributed to the fact that these agencies have their own 
unique approach to HTA. These agencies consider clinical effectiveness and 
comparator studies over cost effectiveness models. Poland, Spain, Italy, Austria, 
Hungary, and Portugal form the low influence HTA agencies that capitalize on the 
lessons learned from more established international HTA systems due to lack of 
in-house qualified personnel and resources for HTA activities. cOnclusiOns: The 
research indicated that there is definitely a cross-influence influence of market 
access decisions between countries across geographies. Decisions are referenced 
informally, via direct contact with other HTA agencies, through international net-
working platforms like EUnetHTA, and INAHTA, or accessing published assess-
ment reports. Variance in the level of influence can be attributed to the age and 
maturity of the HTA, and longevity of assessment performed (specifically cost-
effectiveness assessment).
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PHaRmaCoeConomiC eduCaTion in BRazilian SCHoolS oF PHaRmaCy
Freitas G., Balbinotto G.
Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil
Objectives: The Pharmacoeconomics allows economic evaluation of products and 
services for health and helps a lot the health care decision-making. Therefore, there 
is a need for training of human resources with solid knowledge in pharmacoeco-
nomics in Brazil. However, little is known to what extent Pharmacoeconomics is 
taught in schools of pharmacy in Brazil. The objective of this study was to survey the 
pharmacy schools in Brazil to determine the extent of education in pharmacoeco-
nomics offered during the school year 2012-2013. MethOds: A questionnaire based 
on previous studies [Rascati (1998, 2005, 2013) was developed. This was emailed to 
55 pharmacy schools in Brazil during October and December 2013. The schools were 
selected from the Ministry of Education website. University schools of public and pri-
vate (only those that have high concepts in the National Examination Performance 
of Students) were included. In addition, a search was made in the database direc-
tories of research groups from National Council for Scientific and Technological 
Development (CNPq). Results: Results of the questionnaires sent 55, 14 went 
unanswered. Only one school does not address the teaching of Pharmacoeconomics 
in no time. Most discuss some concepts within various disciplines (see 8:0). Four 
schools have formal disciplines that teach only Pharmacoeconomics or health 
technology assessment (more than 30 hours). All agree that the education of 
pharmacoeconomics is important. In the search for directories of research groups 
were found 23 groups that develop research in the area of Pharmacoeconomics in 
Brazil. cOnclusiOns: Pharmacoeconomics education in Brazil is still in its infancy 
and there is a unique opportunity for well-trained instructors and researchers to 
fill this gap. Provide an education in Pharmacoeconomics to pharmacy and econo-
mists students is especially important in the context of evidence-based decisions 
and when health issues and allocation of scarce resources is a priority for Brazilian 
Health System.
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Horowicz-Mehler N.1, Tao C.2, Faulkner E.C.3, Doyle J.J.4
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Objectives: The nature and frequency of global stakeholder real world data 
(RWD) “ask” is growing and there is an impact of not having RW evidence upon 
market entry such as delayed approval, suboptimal reimbursement and unfavora-
ble re-evaluation. We aimed to assess RWD use for market access (MA) decisions in 
key global markets. MethOds: Search of the HTAWatch database supplemented 
by an online search of MA stakeholders in the US, UK, Australia, and Canada 
for use of RWD to support of initial assessment, re-evaluation or coverage and 
reimbursement recommendations. Use of RWD included safety, effectiveness, 
economic or quality of life studies. We also assessed theevidence level required 
from registry to provider or patient survey data. Results: In the UK, the National 
Health Service uses real-world adherence studies to update national treatment 
guidelines and inform reimbursement. In Australia, the Pharmaceutical Benefits 
Advisory Committee is willing to delay or make temporary decisions in anticipa-
tion of RWD on a product’s clinical effectiveness or economic value message. The 
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exPloRing THe vaRiaBiliTy BeTween diSeaSe TyPe and THe PRoPoRTion 
oF SuBmiSSionS wiTH iCeRS HigHeR THan THe THReSHold THaT aRe 
aCCePTed By HTa agenCieS
Griffiths E.A., Walsh S.C.M.
HERON – A PAREXEL Company, London, UK
Objectives: Health technology assessment (HTA) agencies use an incremental 
cost-effectiveness ratio (ICER) threshold, generally understood to be £30,000 for 
NICE (England), £30,000 for the SMC (Scotland), CAN$50,000 for CADTH (Canada), 
and AUS$42,000 for PBAC (Australia). To inform future submissions, we explored the 
proportion of accepted submissions by disease area and examined any variability in 
the proportion of submissions that were accepted despite the reported ICERs being 
higher than these thresholds. MethOds: All HTA appraisals from January 2000 
to January 2014 from NICE, SMC, CADTH, and PBAC were included in the analysis. 
Multiple technology appraisals, vaccination programmes, requests for advice, and 
submissions for which an ICER could not be determined were excluded from analy-
sis. Appraisals were categorized by BNF disease type and the full responses were 
reviewed; the submitted ICER, recommendation, and reasoning behind the recom-
mendation were extracted. Results: Across all four agencies, 679 submissions 
met the inclusion criteria and 218 submissions included a higher than threshold 
ICER, with 62 (28%) of these accepted. The proportion of submissions with ICERs 
above the threshold that were accepted varied by disease type, ranging from 0% 
(Cardiovascular System) to 50% (Skin). This variability was largely due to the low 
number of submissions with ICERs above the threshold in 14/15 disease type cat-
egories. The remaining disease type (Malignant Disease and Immunosuppression) 
accounted for the majority (59%) of all submissions with ICERs higher than the 
threshold; 36/128 (28%) of these were accepted. Key decision drivers for acceptance 
included unmet clinical need, and condition of participation in a patient access 
or risk sharing scheme. cOnclusiOns: A considerable proportion of submis-
sions were accepted despite ICERs above the threshold, but this proportion varied 
widely between disease types. The majority of disease types had few submissions 
reporting ICERs above the threshold, with the exception of Malignant Disease and 
Immunosuppression.
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exPloRing THe vaRiaBiliTy BeTween diSeaSe TyPe and THe PRoPoRTion 
oF SuBmiSSionS wiTH iCeRS loweR THan THe THReSHold THaT aRe 
RejeCTed By HTa agenCieS
Walsh S.C.M., Griffiths E.A.
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Objectives: Health technology assessment (HTA) agencies use an incremental 
cost-effectiveness ratio (ICER) threshold, generally understood to be £30,000 for 
NICE (England), £30,000 for the SMC (Scotland), CAN$50,000 for CADTH (Canada), 
and AUS$42,000 for PBAC (Australia). To inform future submissions, we explored the 
proportion of rejected submissions by disease area and examined any variability in 
the proportion of submissions that were rejected despite the reported ICERs being 
lower than these thresholds MethOds: All HTA appraisals from January 2000 to 
January 2014 from NICE, SMC, CADTH, and PBAC were included in the analysis. 
Multiple technology appraisals, vaccination programmes, requests for advice, and 
submissions for which an ICER could not be determined were excluded from analy-
sis. Appraisals were categorized by BNF disease type and the full responses were 
reviewed, with the submitted ICER, recommendation, and reasoning behind the 
recommendation extracted. Results: Across all four agencies, 679 submissions 
met the inclusion criteria and 405 submissions included a lower than threshold 
ICER, with 126 (31%) of these submissions rejected. The proportion of submissions 
rejected despite ICERs below the threshold varied by disease type. Disease types 
where a high proportion (≥ 50%) of submissions were rejected despite ICERs below 
the threshold included ‘Respiratory System’ (55% rejected), ‘Central Nervous System’ 
(55%), and ‘Nutrition and Blood’ (55%). Disease areas with a low proportion (≤ 20%) 
of rejected submissions were ‘Infections’ (19%) and ‘Eye’ (20%). Key decision drivers 
for rejection these disease types were due to high levels of uncertainty regarding 
clinical-effectiveness, and subsequent cost-effectiveness. cOnclusiOns: The 
proportion of submissions that were rejected varied dramatically by disease type. 
In some disease types over half of submissions with an ICER below the threshold 
were not recommended largely due to non-robust economic analyses, which may 
indicate inherent underlying difficulties in these disease types in submitting a 
conclusive data package.
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ConSiSTenCy in ReimBuRSemenT deCiSionS aT Canadian HTa agenCieS: 
ineSSS veRSuS CdR
Mills F., Poinas A.C., Siu E., Wyatt G.
Wyatt Health Management, Oakville, ON, Canada
Objectives: To compare the positive recommendation rate and agreement 
between CDR and INESSS. MethOds: In Canada, eligible non-cancer prescription 
drugs approved by Health Canada are reviewed by 2 health technology assess-
ment (HTA) agencies: the Common Drug Review (CDR) and the Institute national 
d’excellence en santé et en services sociaux (INESSS). CDR is part of the Canadian 
Agency for Drugs and Technologies in Health (CADTH), which makes reimburse-
ment recommendations that are considered by provincial and federal plans, with 
the exception of Quebec, in making their formulary coverage decisions. In Quebec 
INESSS performs HTA and issues recommendations to the Regie d’assurance mala-
die Quebec (RAMQ). Prior to INESSS, HTA in Quebec was performed by the Conseil 
du Médicaments (CdM). Using our proprietary CDR Tracker®database we examined 
the recommendations by both agencies and compared recommendation positivity 
and congruence for all drugs which have been reviewed by CDR, up to December 
31, 2013. We separately considered positive and negative recommendations by 
both agencies. Results: The overall positivity rate for CDR recommendations in 
this period was 52%, compared to 66.9% for INESSS. Of the 275 recommendations 
